Beyond, anti-IL-1Ra antibodies could be detected in both active/MAS patients (7/32, 22%; Fig. 3B, center panel), as well as inactive Still’s disease patients (5/31, 16%; Fig. 3B, lower panel) and appeared not associated with non-response to IL-1 targeting therapy (where this information was available, Tables S1and S2) or other clinical disease features (Table S3). Here, IL1B is linked to systemic-onset juvenile idiopathic arthritis.